Literature DB >> 22689904

Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-dihydrouracil in human plasma.

François Coudoré1, Denis Roche, Sandrine Lefeuvre, Delphine Faussot, Eliane M Billaud, Marie-Anne Loriot, Philippe Beaune.   

Abstract

A simple, rapid, sensitive and specific ultra-high-performance liquid chromatography-tandem mass spectrometry method (Waters UPLC-MS-MS) is developed and validated for the quantification of uracil (U) and 5,6-dihydrouracil (UH2) levels in human plasma. Analytes are extracted using ethyl acetate and isopropanol after deproteination, and separated by high-performance liquid chromatography (HPLC) (Acquity UPLC BEH C18 column) in a binary mobile phase system under gradient elution conditions at a flow rate of 0.4 mL/min. 5-Bromo-uracil (UBr) is used as the internal standard. The detection is performed on a triple-quadrupole mass spectrometer via electrospray positive ionization. Multiple reaction monitoring mode using the transitions m/z 112.82 → 70.05, m/z 114.88 → 55.04 and m/z 190.83 → 117.86 is used to quantify U, UH2 and UBr, respectively. The method is linear in the concentration range of 0.625-160.0 ng/mL. The total run time is 4.5 min per injection. Nine-point calibration curve and four-points quality controls are used. Excellent linearity and precision are observed with correlation coefficient (r(2)) > 0.9999. The intra-batch and inter-batch precisions are ≤ 7.3% and ≤ 8.6%, and accuracy is ≤ 17%. The developed method is shown to be suitable for routine quantitative determination of U, UH2 and 5,6-dihydrouracil-to-uracil ratio in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689904     DOI: 10.1093/chromsci/bms085

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  5 in total

Review 1.  A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.

Authors:  Khushaboo Pandey; Rama Shankar Dubey; Bhim Bali Prasad
Journal:  Indian J Clin Biochem       Date:  2015-02-15

2.  Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study.

Authors:  Mirjam de With; Jonathan Knikman; Femke M de Man; Carin A T C Lunenburg; Linda M Henricks; André B P van Kuilenburg; Jan G Maring; Maurice C van Staveren; Niels de Vries; Hilde Rosing; Jos H Beijnen; Dick Pluim; Anil Modak; Alex L T Imholz; Ron H N van Schaik; Jan H M Schellens; Hans Gelderblom; Annemieke Cats; Henk-Jan Guchelaar; Ron H J Mathijssen; Jesse J Swen; Didier Meulendijks
Journal:  Clin Pharmacol Ther       Date:  2022-05-04       Impact factor: 6.903

3.  Trypanosoma brucei (UMP synthase null mutants) are avirulent in mice, but recover virulence upon prolonged culture in vitro while retaining pyrimidine auxotrophy.

Authors:  Han B Ong; Natasha Sienkiewicz; Susan Wyllie; Stephen Patterson; Alan H Fairlamb
Journal:  Mol Microbiol       Date:  2013-09-09       Impact factor: 3.501

Review 4.  DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report.

Authors:  Theodore J Wigle; Elena V Tsvetkova; Stephen A Welch; Richard B Kim
Journal:  Pharmaceutics       Date:  2019-05-01       Impact factor: 6.321

Review 5.  Individualized Dosing of Fluoropyrimidine-Based Chemotherapy to Prevent Severe Fluoropyrimidine-Related Toxicity: What Are the Options?

Authors:  Jonathan E Knikman; Hans Gelderblom; Jos H Beijnen; Annemieke Cats; Henk-Jan Guchelaar; Linda M Henricks
Journal:  Clin Pharmacol Ther       Date:  2020-11-12       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.